- Conditions
- Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
- Interventions
- Ritlecitinib, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 607 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • Encinitas, California • Huntington Beach, California + 31 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Alopecia Areata
- Interventions
- Ritlecitinib 100 mg, Ritlecitinib 50 mg, Placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 17
- States / cities
- Encinitas, California • Miami, Florida • Skokie, Illinois + 11 more
- Conditions
- Vitiligo
- Interventions
- Ritlecitinib, Ritlecitinib 100 mg, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 394 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 22
- States / cities
- Encinitas, California • Huntington Beach, California • Los Angeles, California + 16 more
- Conditions
- Alopecia Areata
- Interventions
- PF-06651600, Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine, Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine
- Drug · Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,057 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Irvine, California + 28 more
- Conditions
- Healthy
- Interventions
- Ritlecitinib 50 mg, Ritlecitinib 200 mg
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Alopecia Areata
- Interventions
- Ritlecitinib 100 mg, Ritlecitinib 50 mg, Placebo - 100 mg, Placebo - 50 mg
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 674 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Hot Springs, Arkansas • Brea, California + 39 more
- Conditions
- Alopecia Areata
- Interventions
- PF-06651600, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 23
- States / cities
- Huntington Beach, California • Irvine, California • Boca Raton, Florida + 17 more
- Conditions
- Healthy Volunteers
- Interventions
- Ritlecitinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
- Interventions
- Ritlecitinib, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,571 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 68
- States / cities
- Scottsdale, Arizona • Bryant, Arkansas • Fountain Valley, California + 47 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Ritlecitinib 50 mg, Ritlecitinib 100 mg, Placebo - 50 mg, Placebo - 100 mg
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 12 more
- Conditions
- Healthy Volunteers
- Interventions
- Ritlecitinib, Tolbutamide
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut